Due to the success of BRAF inhibitors in other tumors, several studies have evaluated the use of BRAF inhibitors with or without MEK inhibitors in metastatic CRC (mCRC) but without achieving the same benefits as in melanoma [19-22]. Here, MAP2K7 is linked to melanoma.